| Serial Number | 87827876 |
| Word Mark | DERAPHAN |
| Filing Date | Friday, March 9, 2018 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, October 22, 2019 |
| Registration Number | 5892113 |
| Registration Date | Tuesday, October 22, 2019 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 24, 2018 |
| Goods and Services | Allergy medications; Amino acid preparations for medical purposes; Antiallergic medicines; Cardiovascular agents for medical purposes; Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Dietary and nutritional supplements; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Nutraceuticals for use as a dietary supplement; Nutritional supplements; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders |
| Translation of Words in Mark | The wording "DERAPHAN" has no meaning in a foreign language. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, March 16, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | Monday, July 2, 2018 |
| First Use In Commerce Date | Monday, July 2, 2018 |
| Party Name | EXCIVA GMBH |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 27 - NOT AVAILABLE |
| Address | VERNON HILLS 69118 DE |
| Party Name | EXCIVA GMBH |
| Party Type | 21 - New Owner After Publication |
| Legal Entity Type | 27 - NOT AVAILABLE |
| Address | HEIDELBERG, IL 69118 |
| Party Name | EXCIVA UG (haftungsbeschränkt) |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Heidelberg 69118 DE |
| Party Name | EXCIVA UG (haftungsbeschränkt) |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Heidelberg 69118 DE |
| Event Date | Event Description |
| Thursday, June 11, 2020 | REVIEW OF CORRESPONDENCE COMPLETE - INFORMATION MADE OF RECORD |
| Wednesday, May 13, 2020 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Sunday, March 8, 2020 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Sunday, March 8, 2020 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Sunday, March 8, 2020 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Sunday, March 8, 2020 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Sunday, March 8, 2020 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Sunday, March 8, 2020 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, October 22, 2019 | REGISTERED-PRINCIPAL REGISTER |
| Thursday, September 19, 2019 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Wednesday, September 18, 2019 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Wednesday, August 7, 2019 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Tuesday, March 5, 2019 | TEAS EXTENSION RECEIVED |
| Tuesday, March 5, 2019 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Tuesday, March 5, 2019 | NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED |
| Tuesday, March 5, 2019 | ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED |
| Tuesday, March 5, 2019 | ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED |
| Tuesday, March 5, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, March 5, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, March 1, 2019 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Monday, February 25, 2019 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Monday, February 25, 2019 | FINAL REFUSAL E-MAILED |
| Monday, February 25, 2019 | SU - FINAL REFUSAL - WRITTEN |
| Monday, February 25, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, February 25, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, February 25, 2019 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, February 25, 2019 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Friday, February 22, 2019 | ASSIGNED TO LIE |
| Monday, February 18, 2019 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, December 5, 2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, December 5, 2018 | NON-FINAL ACTION E-MAILED |
| Wednesday, December 5, 2018 | SU - NON-FINAL ACTION - WRITTEN |
| Saturday, December 1, 2018 | STATEMENT OF USE PROCESSING COMPLETE |
| Wednesday, November 14, 2018 | USE AMENDMENT FILED |
| Saturday, December 1, 2018 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Wednesday, November 14, 2018 | TEAS STATEMENT OF USE RECEIVED |
| Tuesday, September 18, 2018 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, September 18, 2018 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, September 18, 2018 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, September 18, 2018 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, July 24, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 24, 2018 | PUBLISHED FOR OPPOSITION |
| Wednesday, July 4, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, June 21, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, June 21, 2018 | ASSIGNED TO EXAMINER |
| Tuesday, April 3, 2018 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, April 3, 2018 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Thursday, March 15, 2018 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, March 16, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Tuesday, March 13, 2018 | NEW APPLICATION ENTERED IN TRAM |